As the year 2014 comes to a close, Pulmonary Hypertension News – your reliable online source for the latest on pulmonary hypertension treatments, events, clinical trials, and research updates – brings you a concise outline of our “Top 14 Pulmonary Hypertension Stories of 2014:” No. 14 – “Pulmonary Hypertension, Other Lung…

Pulmonary arterial hypertension (PAH)  is a rare condition characterized by high blood pressure of the lung arteries. It costs a great deal in human life lost and life impairment, but how much money is it costing to treat? A recent study published in BMC Health Services Research attempted to answer…

Biopharmaceutical company and leader in pulmonary arterial hypertension (PAH) therapeutics, Actelion Ltd., has just announced it has filed a New Drug Application (NDA) with the US Food and Drug Administration for innovative PAH treatment Uptravi® (selexipag) — the first oral…

United Therapeutics Corporation recently announced that Medtronic, Inc., the world’s third largest medical device company, has forwarded a pre-market approval application to the U.S. Food and Drug Administration (FDA) for their proprietary SynchroMed® II implantable drug infusion system, along with a new catheter, to be used with United Therapeutics’s Remodulin® (treprostinil) injectable, formulated for intravenous treatment of…

The Pulmonary Hypertension Association, one of the country’s most prominent non-profit support, education, advocacy and awareness associations, has just launched a series of online PH learning materials for the holidays, titled, “12 Days of PHA Resources.” According to the PHA, it is common for PH patients to…

Specialized care for those with Pulmonary Hypertension continues to improve across America, with an increasing number of physicians and clinics that are designed to give those with PH the therapy and guidance needed to increase quality of life while living with the disease. Most recently, Kentuckiana Pulmonary Associates of Louisville…

Late-stage cell therapy company Cytori Therapeutics, Inc. will host an informational session about its pivotal STAR clinical trial, which aims to expand knowledge about scleroderma and test a potential treatment for the disease. The company, which is currently developing autologous cell therapies from adipose tissue, will use the information session on January…

Popular online shopping destination eBay, through its subsidiary, eBay, Inc. Foundation, recently awarded the Pulmonary Hypertension Association (PHA) a grant worth $3,000 to help bring patients with pulmonary hypertension (PH) to the association’s next Biennial International Conference and Scientific Sessions. The 2014 sessions took place from June 20-22 in Indianapolis, Indiana,…

A nursing researcher at Louisiana State University Health Sciences Center School of Nursing in New Orleans has found that many factors can impact the quality of life in people with pulmonary hypertension (PH), including mood, anxiety, stress, walking, and the availability of social support. PH is a chronic disease…

An international collaboration of researchers from the United States and China reported that adiponectin (APN), a protein that regulates glucose levels and fatty acid breakdown in the body, may be a naturally-occurring anti-fibrotic agent for systemic sclerosis (SSc). They presented their study at the 2014 American College of Rheumatology Meeting…

Findings from a study entitled “Right ventricular adaptation to pulmonary pressure load in patients with chronic thromboembolic pulmonary hypertension before and after successful pulmonary endarterectomy — a cardiovascular magnetic resonance study,” were recently published in the Journal of Cardiovascular Magnetic Resonance. Chronic thrombolic pulmonary hypertension (CTEPH)…

On Dec 10, 2014 iBio, Inc. revealed progress in developing IBIO-CFB03, a treatment for idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc), and other fibrotic diseases at its Annual Meeting. Unlike other proteins, which are produced by animals or cells in a dish, IBIO-CFB03 will be grown in plants. IPF is a…